Similarly, another study suggested that antibiotic use was associated with reduced TKI efficacy in advanced melanoma and NSCLC [23], but the TKI cohort also included both EGFR and BRAF inhibitors, precluding class-specific conclusions. This evidence concerns the gene BRAF and non-small cell lung carcinoma.